Pharmacokinetics of long-acting (ultralente) insulin preparations

D. E. Seigler, G. M. Olsson, R. F. Agramonte, V. L. Lohman, M. H. Ashby, M. L. Reeves, Jay S Skyler

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The aim of this study was to define and characterize time course of biological action and pharmacokinetics of long-acting ultralente insulin preparations. A further aim was to compare influence of species of origin (beef, pork, human) and specific commercial formulation (Lilly, Novo) on these parameters. Five preparations were studied in 6 to 9 healthy volunteers perpreparation. Dosage was 0.4 U/kg administered subcutaneously in the abdomen. Glucose was clamped for 40 hr at basal levels. Rate of dextrose infusion required to maintain euglycemia was used as the primary means of quantifying biological effectiveness. All ultralente preparations had onset of action between 3.0 and 7.5 hr, with no statistical difference between preparations for onset of action. Likewise, there was no statistical difference between preparations for duration of action, which was greater than 30 hr for all preparations. On the other hand, Lilly human ultralente had an earlier peak of action (8.5 ± 0.9 hr) than beef ultralente, which showed only a subtle peak at a mean of 20.6 ± 3.3 hr. Novo human ultralente resulted in greater total glucose infusion than beef ultralente. Greatest reproducibility of action was with Lilly human ultralente. Curves depicting plasma insulin levels were similar in shape to dextrose infusion profiles for each preparation, thus validating the method. Compared to the total duration of insulin action seen, the peaks of action seen with the pork and human ultralente insulin preparations were quite broad and of relatively small magnitude. As a consequence of the breadth of the action peaks and the prolonged duration of action of ultralente insulin, any of the ultralente formulations should be suitable to provide basal insulinemia.

Original languageEnglish
Pages (from-to)267-273
Number of pages7
JournalDiabetes, Nutrition and Metabolism - Clinical and Experimental
Volume4
Issue number4
StatePublished - Dec 1 1991

Fingerprint

Ultralente Insulin
Long-Acting Insulin
pharmacokinetics
insulin
Pharmacokinetics
Glucose
glucose
beef
pork
duration
Insulin
hyperinsulinemia
abdomen
reproducibility
Abdomen
volunteers
Healthy Volunteers
Red Meat
dosage

ASJC Scopus subject areas

  • Food Science
  • Endocrinology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Seigler, D. E., Olsson, G. M., Agramonte, R. F., Lohman, V. L., Ashby, M. H., Reeves, M. L., & Skyler, J. S. (1991). Pharmacokinetics of long-acting (ultralente) insulin preparations. Diabetes, Nutrition and Metabolism - Clinical and Experimental, 4(4), 267-273.

Pharmacokinetics of long-acting (ultralente) insulin preparations. / Seigler, D. E.; Olsson, G. M.; Agramonte, R. F.; Lohman, V. L.; Ashby, M. H.; Reeves, M. L.; Skyler, Jay S.

In: Diabetes, Nutrition and Metabolism - Clinical and Experimental, Vol. 4, No. 4, 01.12.1991, p. 267-273.

Research output: Contribution to journalArticle

Seigler, DE, Olsson, GM, Agramonte, RF, Lohman, VL, Ashby, MH, Reeves, ML & Skyler, JS 1991, 'Pharmacokinetics of long-acting (ultralente) insulin preparations', Diabetes, Nutrition and Metabolism - Clinical and Experimental, vol. 4, no. 4, pp. 267-273.
Seigler DE, Olsson GM, Agramonte RF, Lohman VL, Ashby MH, Reeves ML et al. Pharmacokinetics of long-acting (ultralente) insulin preparations. Diabetes, Nutrition and Metabolism - Clinical and Experimental. 1991 Dec 1;4(4):267-273.
Seigler, D. E. ; Olsson, G. M. ; Agramonte, R. F. ; Lohman, V. L. ; Ashby, M. H. ; Reeves, M. L. ; Skyler, Jay S. / Pharmacokinetics of long-acting (ultralente) insulin preparations. In: Diabetes, Nutrition and Metabolism - Clinical and Experimental. 1991 ; Vol. 4, No. 4. pp. 267-273.
@article{a032fbbcbe46458788c3b35788a6f27f,
title = "Pharmacokinetics of long-acting (ultralente) insulin preparations",
abstract = "The aim of this study was to define and characterize time course of biological action and pharmacokinetics of long-acting ultralente insulin preparations. A further aim was to compare influence of species of origin (beef, pork, human) and specific commercial formulation (Lilly, Novo) on these parameters. Five preparations were studied in 6 to 9 healthy volunteers perpreparation. Dosage was 0.4 U/kg administered subcutaneously in the abdomen. Glucose was clamped for 40 hr at basal levels. Rate of dextrose infusion required to maintain euglycemia was used as the primary means of quantifying biological effectiveness. All ultralente preparations had onset of action between 3.0 and 7.5 hr, with no statistical difference between preparations for onset of action. Likewise, there was no statistical difference between preparations for duration of action, which was greater than 30 hr for all preparations. On the other hand, Lilly human ultralente had an earlier peak of action (8.5 ± 0.9 hr) than beef ultralente, which showed only a subtle peak at a mean of 20.6 ± 3.3 hr. Novo human ultralente resulted in greater total glucose infusion than beef ultralente. Greatest reproducibility of action was with Lilly human ultralente. Curves depicting plasma insulin levels were similar in shape to dextrose infusion profiles for each preparation, thus validating the method. Compared to the total duration of insulin action seen, the peaks of action seen with the pork and human ultralente insulin preparations were quite broad and of relatively small magnitude. As a consequence of the breadth of the action peaks and the prolonged duration of action of ultralente insulin, any of the ultralente formulations should be suitable to provide basal insulinemia.",
author = "Seigler, {D. E.} and Olsson, {G. M.} and Agramonte, {R. F.} and Lohman, {V. L.} and Ashby, {M. H.} and Reeves, {M. L.} and Skyler, {Jay S}",
year = "1991",
month = "12",
day = "1",
language = "English",
volume = "4",
pages = "267--273",
journal = "Diabetes, Nutrition and Metabolism - Clinical and Experimental",
issn = "0394-3402",
publisher = "Editrice Kurtis s.r.l.",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetics of long-acting (ultralente) insulin preparations

AU - Seigler, D. E.

AU - Olsson, G. M.

AU - Agramonte, R. F.

AU - Lohman, V. L.

AU - Ashby, M. H.

AU - Reeves, M. L.

AU - Skyler, Jay S

PY - 1991/12/1

Y1 - 1991/12/1

N2 - The aim of this study was to define and characterize time course of biological action and pharmacokinetics of long-acting ultralente insulin preparations. A further aim was to compare influence of species of origin (beef, pork, human) and specific commercial formulation (Lilly, Novo) on these parameters. Five preparations were studied in 6 to 9 healthy volunteers perpreparation. Dosage was 0.4 U/kg administered subcutaneously in the abdomen. Glucose was clamped for 40 hr at basal levels. Rate of dextrose infusion required to maintain euglycemia was used as the primary means of quantifying biological effectiveness. All ultralente preparations had onset of action between 3.0 and 7.5 hr, with no statistical difference between preparations for onset of action. Likewise, there was no statistical difference between preparations for duration of action, which was greater than 30 hr for all preparations. On the other hand, Lilly human ultralente had an earlier peak of action (8.5 ± 0.9 hr) than beef ultralente, which showed only a subtle peak at a mean of 20.6 ± 3.3 hr. Novo human ultralente resulted in greater total glucose infusion than beef ultralente. Greatest reproducibility of action was with Lilly human ultralente. Curves depicting plasma insulin levels were similar in shape to dextrose infusion profiles for each preparation, thus validating the method. Compared to the total duration of insulin action seen, the peaks of action seen with the pork and human ultralente insulin preparations were quite broad and of relatively small magnitude. As a consequence of the breadth of the action peaks and the prolonged duration of action of ultralente insulin, any of the ultralente formulations should be suitable to provide basal insulinemia.

AB - The aim of this study was to define and characterize time course of biological action and pharmacokinetics of long-acting ultralente insulin preparations. A further aim was to compare influence of species of origin (beef, pork, human) and specific commercial formulation (Lilly, Novo) on these parameters. Five preparations were studied in 6 to 9 healthy volunteers perpreparation. Dosage was 0.4 U/kg administered subcutaneously in the abdomen. Glucose was clamped for 40 hr at basal levels. Rate of dextrose infusion required to maintain euglycemia was used as the primary means of quantifying biological effectiveness. All ultralente preparations had onset of action between 3.0 and 7.5 hr, with no statistical difference between preparations for onset of action. Likewise, there was no statistical difference between preparations for duration of action, which was greater than 30 hr for all preparations. On the other hand, Lilly human ultralente had an earlier peak of action (8.5 ± 0.9 hr) than beef ultralente, which showed only a subtle peak at a mean of 20.6 ± 3.3 hr. Novo human ultralente resulted in greater total glucose infusion than beef ultralente. Greatest reproducibility of action was with Lilly human ultralente. Curves depicting plasma insulin levels were similar in shape to dextrose infusion profiles for each preparation, thus validating the method. Compared to the total duration of insulin action seen, the peaks of action seen with the pork and human ultralente insulin preparations were quite broad and of relatively small magnitude. As a consequence of the breadth of the action peaks and the prolonged duration of action of ultralente insulin, any of the ultralente formulations should be suitable to provide basal insulinemia.

UR - http://www.scopus.com/inward/record.url?scp=0026349077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026349077&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 267

EP - 273

JO - Diabetes, Nutrition and Metabolism - Clinical and Experimental

JF - Diabetes, Nutrition and Metabolism - Clinical and Experimental

SN - 0394-3402

IS - 4

ER -